Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management
Authors:
- Michael SchwakeMSMichael Schwake
- Michael MütherMichael Müther
- Ann-Katrin BrunsABAnn-Katrin Bruns
- Bastian ZinnhardtBZBastian Zinnhardt
- Nils WarnekeNWNils Warneke
- Markus HollingMHMarkus Holling
- Stephanie SchipmannSSStephanie Schipmann
- Benjamin BrokinkelBBBenjamin Brokinkel
- Johannes WölferJWJohannes Wölfer
- Walter StummerWSWalter Stummer
- Oliver GrauerOGOliver Grauer
Open Access
Abstract
Background: Concepts improving local tumor control in high-grade glioma (HGG) are desperately needed. The aim of this study is to report an extended series of cases treated with a combination of 5-ALA-fluorescence-guided resection (FGR) and intracavitary thermotherapy with superparamagnetic iron oxide nanoparticles (SPION). Methods: We conducted a single-center retrospective review of all recurrent HGG treated with FGR and intracavitary thermotherapy (n = 18). Patients underwent six hyperthermia sessions in an alternating magnetic field and received additional adjuvant therapies on a case-by-case basis. Results: Nine patients were treated for first tumor recurrence; all other patients had suffered at least two recurrences. Nine patients received combined radiotherapy and thermotherapy. The median progression-free survival was 5.5 (95% CI: 4.67–6.13) months and median overall survival was 9.5 (95% CI: 7.12–11.79) months. No major side effects were observed during active treatment. Thirteen patients (72%) developed cerebral edema and more clinical symptoms during follow-up and were initially treated with dexamethasone. Six (33%) of these patients underwent surgical removal of nanoparticles due to refractory edema. Conclusions: The combination of FGR and intracavitary thermotherapy with SPION provides a new treatment option for improving local tumor control in recurrent HGG. The development of cerebral edema is a major issue requiring further refinements of the treatment protocol.Keywords
This publication has 58 references indexed in Scilit:
- Improving the Extent of Malignant Glioma Resection by Dual Intraoperative Visualization ApproachPLOS ONE, 2012
- Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarkerJournal of Neurosurgery, 2011
- Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous SystemInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiformeJournal of Neuro-Oncology, 2010
- Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre studyThe Lancet Oncology, 2010
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE StudyJournal of Clinical Oncology, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Deferoxamine Iron Chelation Increases δ‐Aminolevulinic Acid Induced Protoporphyrin IX in Xenograft Glioma ModelPhotochemistry and Photobiology, 2010
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005